Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

29.30
-1.1300-3.71%
Post-market: 29.600.3000+1.02%17:56 EDT
Volume:3.95M
Turnover:115.44M
Market Cap:2.30B
PE:-6.75
High:30.10
Open:30.07
Low:28.63
Close:30.43
52wk High:45.14
52wk Low:22.10
Shares:78.49M
Float Shares:73.02M
Volume Ratio:2.29
T/O Rate:5.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:3.22
PE(LYR):-7.51

Loading ...

How Investors May Respond To Celldex Therapeutics Stock After Phase 3 Trial Success

Simply Wall St.
·
Oct 05

Celldex (CLDX) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Oct 03

Celldex adverse event concerns overblown, says H.C. Wainwright

TIPRANKS
·
Oct 02

Celldex Therapeutics Price Target Maintained with a $64.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 02

Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Nanobiotix (NBTX) and Senseonics Holdings (SENS)

TIPRANKS
·
Sep 28

Belgium's Celyad H1 Net Loss Narrows on Lower Expenses

Reuters
·
Sep 24

Canaccord Genuity Sticks to Their Buy Rating for Celldex (CLDX)

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)

TIPRANKS
·
Sep 23

US Research Roundup- Allstate, Autozone, Vertex Pharmaceuticals

Reuters
·
Sep 23

Top Midday Decliners

MT Newswires Live
·
Sep 23

Celldex Therapeutics is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 22

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

Reuters
·
Sep 22

Celldex price target raised to $64 from $42 at H.C. Wainwright

TIPRANKS
·
Sep 22

Celldex Shares Slip as Safety Concerns Cloud Skin Drug Trial Win

Reuters
·
Sep 22

Celldex Falls After Two Probable Anaphylaxis Cases in Trials

Reuters
·
Sep 22

Celldex falls -5.1%

TIPRANKS
·
Sep 22

Celldex Therapeutics Shares Fall 1.9% After Data from Late-Stage Trials of Its Skin Disease Drug

THOMSON REUTERS
·
Sep 22

Celldex Therapeutics Shares Reverse Course; Last Down 19.2% Premarket

THOMSON REUTERS
·
Sep 22

Celldex Therapeutics Shares up 21% Premarket After Co's Skin Condition Drug Barzolvolimab Meets Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Sep 22